360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Horizon Discovery Ltd

Type: Company

Name: Horizon Discovery Ltd

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Eisai Co Ltd

[Eisai]’s [H3 Biomedicine], [Horizon Discovery] identify cancer targets

Home » Blogs » Related Biotechnology, Pharmaceutical and Healthcare News[Eisai Co. Ltd.]’s US cancer genomics subsidiary [H3 Biomedicine Inc.] and five-year-old translational genomics and personalized medicine firm [Horizon Discovery Ltd.] will collaborate ... [Published BioPortfolio - May 15 2013]

Entities: Horizon Discovery Ltd, Eisai Co Ltd, Biomedicine

First reported May 13 2013 - Updated May 13 2013 - 1 reports

A pair of model-building aficionados

SANTA CLARA, Calif.Early April ushered in the signing of a deal between drug discovery and development service company and personalized medicine research tools provider Horizon Discovery in Cambridge, U.K., to develop novel in-vivo models for drug discovery. ... [Published Drug Discovery News - May 13 2013]

Entities: Horizon Discovery Ltd, Cell Lines, Oncology

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Johnson Matthey plc

Cambridge deals top half a billion dollars in Apri...

The Cambridge technology cluster in the UK continued to punch above its weight in global dealflow as transaction value in April topped $0.5 billion.Around two-thirds of the deal total was driven by BioMedTech and healthcare companies. The only major non-bio ... [Published Business Weekly UK - May 02 2013]

Entities: Horizon Discovery Ltd, Apricus Biosciences Inc, Johnson Matthey plc, Chemical

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Crown Bioscience and Horizon Discovery Announce Exclusive Two Year Agreement to Offer Combined Solutions for In Vivo Drug Discovery Model Development

Crown Bioscience Inc. (Crown), a leading global drug discovery and development service company, and Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, announced they have signed an ... [Published Pharma-Mag - May 02 2013]

Entities: Horizon Discovery Ltd, In Vivo, Drug Discovery, Cell Lines

First reported May 01 2013 - Updated May 01 2013 - 1 reports

FDA Food & Drug Administration

Cara partners with Maruishi for Japanese rights to CR845

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug ... [Published MVM Life Science - May 01 2013]

Entities: Horizon Discovery Ltd, BioVex Inc, primary endpoint, FDA Food & Drug Administration

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

[AZ] partners with [Horizon Discovery] to target K-Ras mutant cancers

Home » Blogs » Related Biotechnology, Pharmaceutical and Healthcare News[AstraZeneca PLC] has licensed exclusive rights to translational research firm [Horizon Discovery Ltd.]’s kinase target program HD001, which the Big Pharma is eyeing for the development ... [Published BioPortfolio - Apr 30 2013]

Entities: Horizon Discovery Ltd, Mutant, Cancer

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

AstraZeneca PLC

Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca

Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. ... [Published Pharma-Mag - Apr 23 2013]

Entities: Horizon Discovery Ltd, AstraZeneca PLC, Oncology, Drug Discovery

First reported Apr 22 2013 - Updated Apr 23 2013 - 1 reports

AstraZeneca inks cancer deals with Bind and Horizon

AstraZeneca has signed a nanomedicines pact with Bind Therapeutics in a deal which could be worth $200 million to the privately-held US biopharma firm.The firms will work together to develop what Bind calls an "Accurin", a targeted and programmable cancer ... [Published Pharma Times - Apr 22 2013]

Entities: Horizon Discovery Ltd, AstraZeneca PLC, Cancer

First reported Apr 22 2013 - Updated Apr 23 2013 - 2 reports

$100m AstraZeneca blockbuster for Horizon

Cambridge UK personalised medicines pioneer Horizon Discovery has landed a $100 million blockbuster deal with global pharma giant AstraZeneca.And the initial programme could trigger annual multimillion dollar hauls for Horizon on top of the upfront w ... [Published Business Weekly UK - Apr 22 2013]

Entities: Horizon Discovery Ltd, AstraZeneca PLC, Cancer, Kinase, Mutant

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Personalised medicines gospel reaches papal territory

Personalised medicines technology from Horizon Discovery division Horizon Diagnostics (HDx) in Cambridge UK can now be distributed in Vatican City as part of a new deal with an Italian partner.Business Weekly understands that the deal will bring Horizon ... [Published Business Weekly UK - Apr 15 2013]

Entities: Horizon Discovery Ltd, Pharmacogenetics, Assay

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Horizon Discovery and Diatech Pharmacogenetics Sign Distribution Agreement

Agreement covers distribution of Horizon Diagnostics’ molecular reference standards products in Italy, San Marino and Vatican City. ... [Published Technology Networks - Apr 15 2013]

Entities: Horizon Discovery Ltd, Pharmacogenetics, Diagnostics, San Marino

First reported Apr 05 2013 - Updated Apr 05 2013 - 1 reports

Crown Bioscience, Horizon sign two-year drug discovery collaboration agreement

US-based drug discovery and development service company Crown Bioscience and Horizon Discovery have entered into a two year collaboration agreement to provide combined solutions for in vivo model development. ... [Published PBR - News - Apr 05 2013]

Entities: Horizon Discovery Ltd, collaboration, In Vivo

Quotes

Commenting on the sought after title of Business of the Year, Sue Davies, Head of Human Resources at Bourne Leisure said, "As one of the larger employers in Hertfordshire it's great to be recognised in this way. We work alongside many other businesses including Hemel Stags and we are also a member of the local Wildlife Trust. Our team really enjoys getting out and about, helping and working in the community whenever they can and many do charity work and fundraising locally. We are very much looking forward to partnering with KISS Communications over the coming months."

Business of the Year winner, Bourne Leisure wins marketing support package from KISS Communications [Published Prlog - May 22 2013]

"We’re looking to identify new products from the marine environment, such as antibiotics, and find ways to sustainably manufacture them on an industrial scale. We at Strathclyde excel in our ability to find new compounds – such as anti-cancer and anti-infective drugs – and have decades’ worth of experience in testing how effective they are."

Europe researches SeabioTech [Published Compute Scotland - May 16 2013]

...Ms Galbraith said that AstraZeneca "has a proven track record of collaborating on early stage discovery projects with innovative organisations like Horizon, partnering their cutting-edge science with our strong oncology expertise"

AstraZeneca inks cancer deals with Bind and Horizon [Published Pharma Times - Apr 22 2013]

More Content

sort by: Date \| Relevance
INVESTEC STRUCTURED PRODUCTS CALCULUS VCT PLC -... [Published ADVFN India - May 22 2013]
Investec Structured : Annual Financial Report [Published Investegate - May 22 2013]
Business of the Year winner, Bourne Leisure win... [Published Prlog - May 22 2013]
Europe researches SeabioTech [Published Compute Scotland - May 16 2013]
[Eisai]’s [H3 Biomedicine], [Horizon Discovery]... [Published BioPortfolio - May 15 2013]
A pair of model-building aficionados [Published Drug Discovery News - May 13 2013]
Disruptive technology under Cambridge microscope [Published Business Weekly UK - May 07 2013]
BlueGnome VC dodge pays off for Cambridge Enter... [Published Cabume - May 07 2013]
Cambridge deals top half a billion dollars in A... [Published Business Weekly UK - May 02 2013]
Crown Bioscience and Horizon Discovery Announce... [Published Pharma-Mag - May 02 2013]
Cara partners with Maruishi for Japanese rights... [Published MVM Life Science - May 01 2013]
[AZ] partners with [Horizon Discovery] to targe... [Published BioPortfolio - Apr 30 2013]
Alchemia, AstraZeneca Partner on $240M Multi-Ta... [Published Genetic Engineering News - Apr 23 2013]
Horizon Discovery Announces Oncology Drug Disco... [Published Pharma-Mag - Apr 23 2013]
$100m AstraZeneca blockbuster for Horizon [Published Business Weekly UK - Apr 22 2013]
Horizon Discovery Announces Oncology Drug Disco... [Published AstraZeneca - Apr 22 2013]
AstraZeneca inks cancer deals with Bind and Hor... [Published Pharma Times - Apr 22 2013]
Spirit of Spock powers new tech enterprise [Published Business Weekly UK - Apr 16 2013]
Personalised medicines gospel reaches papal ter... [Published Business Weekly UK - Apr 15 2013]
Horizon Discovery and Diatech Pharmacogenetics ... [Published Technology Networks - Apr 15 2013]
DFJ Esprit To Close Another Fund Of Up To $15M ... [Published TechCrunch - Apr 05 2013]
Crown Bioscience, Horizon sign two-year drug di... [Published PBR - News - Apr 05 2013]
Horizon Discovery Establishes Three New Centers... [Published Business Wire Science: Science News - Mar 04 2013]
Horizon Discovery Establishes Three New Centers... [Published Business Wire Health News - Mar 04 2013]
Horizon Discovery signs research service collab... [Published PharmaBiz - Jan 15 2013]
New Hope for Dementia Patients [Published ThirdAge - Oct 09 2012]

Blogs

sort by: Date \| Relevance
Crown Bioscience and Horizon Discovery Announce... [Published Pharma-Mag - May 02 2013] Crown Bioscience Inc. (Crown), a leading global drug discovery and development service company, and Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, announced they have signed an ...
Horizon Discovery Announces Oncology Drug Disco... [Published Pharma-Mag - Apr 23 2013] Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. ...
DFJ Esprit To Close Another Fund Of Up To $15M ... [Published TechCrunch - Apr 05 2013] Angel investing in Europe is getting another boost: DFJ Esprit , a UK-based division of the Draper Fisher Jurvetson network of VCs, is preparing to close its second EIS Angel Co-Investment fund, up to £10 million ($15 million) that will be used to ...
Crown Bioscience, Horizon sign two-year drug di... [Published PBR - News - Apr 05 2013] US-based drug discovery and development service company Crown Bioscience and Horizon Discovery have entered into a two year collaboration agreement to provide combined solutions for in vivo model development. ...

Press Releases

sort by: Date \| Relevance
Horizon Discovery Establishes Three New Centers... [Published Business Wire Science: Science News - Mar 04 2013]
Horizon Discovery Establishes Three New Centers... [Published Business Wire Health News - Mar 04 2013]